Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial

Induction of lung mucosal immunity by a next-generation inhaled aerosol COVID-19 vaccine: an open-label, multi-arm phase 1 clinical trial

Abstract The current COVID-19 vaccines are suboptimal against the evolving SARS-CoV-2 variants, particularly in high-risk populations. A next-generation vaccine strategy capable of effective induction of respiratory mucosal immunity remains to be clinically developed. Here, we report an open-label,...

Full description

Saved in:
Bibliographic Details
Main Authors: Mangalakumari Jeyanathan, Sam Afkhami, Michael R. D’Agostino, Imran Satia, Dominik K. Fritz, Kate Miyasaki, Jann C. Ang, Anna Zganiacz, Karen J. Howie, Marilyn Swinton, Emilio Aguirre, Michael B. Zheng, Natallia Kazhdan, Anna Dvorkin-Gheva, Lawrence Mbuagbaw, Maria Fe C. Medina, Nermin Diab, Danica L. Brister, Gail M. Gauvreau, Brian D. Lichty, Matthew S. Miller, Fiona Smaill, Zhou Xing
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-60726-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-025-60726-0

Similar Items